Partnered products

4SC has out-licensed and partnered drug candidates to several national and international pharma and biotech companies.

Licensed to Immunic Inc.

The IMU-366 program comprises one lead compound and a family of orally available small molecule inhibitors of RORγt – a nuclear receptor responsible for gene expression of key cytokines involved in various immune or autoimmune diseases.

Share this page:

Follow us on: